CD22 and neoplasm: The treatment process of CAR‐T cells involves obtaining T cells from patients, expressing CAR with specific binding to tumor antigen in T cells, infusing expanded CAR‐T cells back into the patients, and monitoring CAR‐T treatment responses.[7] CAR‐T cell manufacturing requires isolating autologous T cells from patients' peripheral blood mononuclear cells (PBMCs) and infecting them with lentivirus expressing CAR with specific binding to tumor antigens, such as CD19, CD20, and CD22.